Foghorn Therapeutics周四表示，在一项早期试验中未能显示出足够疗效后，已停止开发与礼来公司合作的一种实验性抗癌药物。
Foghorn Therapeutics said on Thursday it has discontinued development of an experimental cancer drug partnered with Eli Lilly after it failed to show enough benefit in an early-stage trial.